Innovation of the process of production of veterinary vaccines against leptospirosis and disease (Q9935): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 2 languages: Changing unique label-description pair)
(‎Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement)
Property / financed by
 
Property / financed by: Directorate-General for Regional and Urban Policy / rank
Normal rank
 

Revision as of 15:23, 28 October 2020

Project Q9935 in Czech Republic
Language Label Description Also known as
English
Innovation of the process of production of veterinary vaccines against leptospirosis and disease
Project Q9935 in Czech Republic

    Statements

    0 references
    7,500,000.0 Czech koruna
    0 references
    300,000.0 Euro
    10 January 2020
    0 references
    30,000,000.0 Czech koruna
    0 references
    1,200,000.0 Euro
    10 January 2020
    0 references
    25 percent
    0 references
    19 November 2015
    0 references
    23 August 2018
    0 references
    1 October 2018
    0 references
    Bioveta, a.s.
    0 references
    0 references

    49°18'9.65"N, 17°4'54.52"E
    0 references

    49°17'53.88"N, 17°6'21.31"E
    0 references
    68323
    0 references
    Předmětem projektu je inovace procesu výroby a kultivace vakcín proti leptospiróze a borelióze založená na pomnožení spirochet fermentační kultivací v průmyslovém bioreaktoru. Inovace procesu bude realizována formou zavedení nové technologie výroby antigenů. Inovace se týká celé řady přípravků (např. Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofel B, Biocan B, Borrelym). V rámci projektu bude pořízena technologie pro nový způsob výroby, a to bioreaktory, formulační kotel a ultrafiltr. a. (Czech)
    0 references
    The subject of the project is innovation of the process of production and cultivation of leptospirosis and borrelia vaccines based on the enhancement of spirochetes by fermentation in an industrial bioreactor. The innovation of the process will be implemented through the introduction of a new antigen production technology. Innovation concerns a wide range of products (e.g. Biocan L, Biocan Novel L4, B BioBos L, BioBos L6, Biofel B, Biocan B, Borrelym). The project will acquire technology for a new production method, namely bioreactors, formulation boiler and ultrafilter. a. (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/15_014/0004382
    0 references